NNBP Nanobac Pharmaceuticals Inc (CE)

TAMPA, FL ("Nanobac" or "the Company") announces an audio interview of scientists at Mayo Clinic that discusses calcifying nanoparticles (CNPs or NPs) in arterial and kidney stone disease. The researchers discuss CNPs both as a cause and accelerant of diseases. Please go to Nanobac's website or www.lifelines.tv and listen to episode 7.

About Pathologic Calcific Diseases

Irregular calcium deposits are implicated in inflammatory diseases such as heart disease, prostatitis and arthritis, and stone forming diseases such as kidney and gall stones. The impact on the health care delivery system could be substantial given that billions of dollars are spent each year on treating diseases associated with CNPs. The company is well positioned to take advantage of numerous diagnostic and therapeutic opportunities in these sectors.

Nanobac Pharmaceuticals, Inc. has moved its corporate office to 3000 Bayport Drive, Suite 910 Tampa, Florida 33607. The new phone number is 813 865-1125. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.

Contact: Nanobac Pharmaceuticals, Tampa Brady Millican 813-865-1125 Email Contact

Nanobac Pharmaceuticals (CE) (USOTC:NNBP)
Historical Stock Chart
From Nov 2024 to Dec 2024

Nanobac Pharmaceuticals (CE) (USOTC:NNBP)
Historical Stock Chart
From Dec 2023 to Dec 2024